Γ

The Buyers, The Partners, And The Companies You’ve Been Trying To Reach Will All Be In One Building This May

Three days. 2,000+ attendees. The partnering app lets you book meetings before you arrive.

Tuesday: close a deal in the hallway. Tuesday night: biotech comedy show. Wednesday: meet the startup that’s going to change your industry. Thursday night: DJ after party. Sleep when you get home.

Partners on Stage

Investors & Funders Confirmed

The Kind of Business that Gets Done at SynBioBeta

"SynBioBeta is an incredible meeting place. I met BitBiome there, and we ended up using their amazing technology to find enzymes that we're now engineering into new strains for new products. I wouldn't have made this connection and collaboration without attending SynBioBeta."
"SynBioBeta is an incredible meeting place. I met BitBiome there, and we ended up using their amazing technology to find enzymes that we're now engineering into new strains for new products. I wouldn't have made this connection and collaboration without attending SynBioBeta."

Zack Abbott

Founder & CEO, ZBiotics

"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."

Luis Cascao-Pereira

Head of Digital Biology, IFF

"SynBioBeta creates the kind of environment where real collaborations start. That's where I met the team at IFF, and the conversation quickly turned into a project to improve one of their enzymes."
"SynBioBeta creates the kind of environment where real collaborations start. That's where I met the team at IFF, and the conversation quickly turned into a project to improve one of their enzymes."

Matthew Thompson

VP Industrial Biotech, Biomatter

Companies Doing Business at SynBioBeta

Sessions to Watch

1

Main Stage Panel

11:05 AM

-

11:30 AM

Tools & Tech

From AI protein design to real-world commercial impact: powering the next wave of everyday products

For more than a century, everyday products - from detergents and shampoos to textiles and packaging - have relied on petrochemicals and harsh industrial processes. Today, AI-driven protein design is opening a radically different path: creating custom enzymes and biomolecules that outperform traditional chemistry while reducing environmental impact. This session explores how advances in computational protein design and machine learning enable the rational creation of enzymes tailored for home care, personal care, and next-generation materials—moving beyond incremental discovery to purpose-built performance under real industrial conditions. Critically, this highlights how AI-driven design is being translated into commercially deployed products at scale with partners and customers.

Get a Ticket

1

Main Stage Panel

11:05 AM

-

11:30 AM

Tools & Tech

From AI protein design to real-world commercial impact: powering the next wave of everyday products

For more than a century, everyday products - from detergents and shampoos to textiles and packaging - have relied on petrochemicals and harsh industrial processes. Today, AI-driven protein design is opening a radically different path: creating custom enzymes and biomolecules that outperform traditional chemistry while reducing environmental impact. This session explores how advances in computational protein design and machine learning enable the rational creation of enzymes tailored for home care, personal care, and next-generation materials—moving beyond incremental discovery to purpose-built performance under real industrial conditions. Critically, this highlights how AI-driven design is being translated into commercially deployed products at scale with partners and customers.

Get a Ticket

2

Main Stage Panel

2:25 PM

-

2:55 PM

Tools & Tech

Engineering Resilient Pharma Supply Chains with Biology

For decades, pharmaceutical supply chains were optimized for cost and scale, stretching across continents to source critical active ingredients. But fragility has made resilience a strategic imperative. Synthetic biology offers a new model: onshoring the production of essential APIs by programming cells to manufacture small molecules, peptides, and novel amino acids with precision and scalability. Instead of relying on distant chemical supply networks, biology becomes the factory—flexible, distributed, and programmable. This session explores how engineered microbes and directed evolution platforms are rebuilding pharma supply chains from the molecular level up, enabling secure, responsive, and locally anchored production of the medicines the world depends on.

Get a Ticket

2

Main Stage Panel

2:25 PM

-

2:55 PM

Tools & Tech

Engineering Resilient Pharma Supply Chains with Biology

For decades, pharmaceutical supply chains were optimized for cost and scale, stretching across continents to source critical active ingredients. But fragility has made resilience a strategic imperative. Synthetic biology offers a new model: onshoring the production of essential APIs by programming cells to manufacture small molecules, peptides, and novel amino acids with precision and scalability. Instead of relying on distant chemical supply networks, biology becomes the factory—flexible, distributed, and programmable. This session explores how engineered microbes and directed evolution platforms are rebuilding pharma supply chains from the molecular level up, enabling secure, responsive, and locally anchored production of the medicines the world depends on.

Get a Ticket

3

Breakout Session

3:30 PM

-

4:15 PM

Biomanufacturing

Full Stack Bio: How Can Biotech Collaborate to Achieve Scale with Competitive COGS

Scaling bio-based products requires integrated technical collaboration across strain engineering, fermentation, downstream processing, and analytics. Full-stack approaches—where startups, CDMOs, and platform technology providers align early on—can optimize yield, reduce variability, and lower cost of goods (COGS) at commercial scale. This session explores case studies of cross-company collaboration, from co-development of microbial strains and bioreactor designs to shared process analytics and predictive modeling. Hear how teams are breaking down technical silos to accelerate scale-up, improve reproducibility, and create competitive, sustainable manufacturing solutions that bring synthetic biology products from the lab to the market efficiently.

Get a Ticket

3

Breakout Session

3:30 PM

-

4:15 PM

Biomanufacturing

Full Stack Bio: How Can Biotech Collaborate to Achieve Scale with Competitive COGS

Scaling bio-based products requires integrated technical collaboration across strain engineering, fermentation, downstream processing, and analytics. Full-stack approaches—where startups, CDMOs, and platform technology providers align early on—can optimize yield, reduce variability, and lower cost of goods (COGS) at commercial scale. This session explores case studies of cross-company collaboration, from co-development of microbial strains and bioreactor designs to shared process analytics and predictive modeling. Hear how teams are breaking down technical silos to accelerate scale-up, improve reproducibility, and create competitive, sustainable manufacturing solutions that bring synthetic biology products from the lab to the market efficiently.

Get a Ticket